Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Bristol-Myers Squibb
National Cancer Institute (NCI)
All India Institute of Medical Sciences
Bristol-Myers Squibb
Daiichi Sankyo
AbbVie
University Health Network, Toronto
Karyopharm Therapeutics Inc
Fudan University
Privo Technologies
Tata Memorial Centre
Vasgene Therapeutics, Inc
Gruppo Oncologico del Nord-Ovest
Bio-Thera Solutions
Leiden University Medical Center
Tongji Hospital
Qingdao Central Hospital
Shanghai Jiao Tong University School of Medicine